Information Provided By:
Fly News Breaks for July 14, 2016
HZNP
Jul 14, 2016 | 07:34 EDT
Brean Capital believes Horizon Pharma shares are valued very inexpensively. After the company made minor changes to its Horizon Cares Program, the firm noted management said it fine tunes the program on a regular basis to optimize long-term revenue and gross to net is expected to improve at the expense of volume growth. Brean Capital reiterated its Buy rating and $30 price target on Horizon Pharma shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.